Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
7Customers
3Debt Items
4Related Chains
Source-Backed Evidence Depth
Kiora Pharmaceuticals, Inc. (KPRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
3Distinct source URLs
12High confidence
0.857Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Kiora Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
PHOTOSWITCH-THERAPEUTICS-INC
PHOTOSWITCH-THERAPEUTICS-INC
90%
On May 1, 2020, we, through our subsidiary Bayon, entered into an agreement with Photoswitch Therapeutics, Inc. ("Photoswitch") granting to us access to certain patent applications and intellectual p…
UNIVERSITY-OF-CALIFORNIA
UNIVERSITY-OF-CALIFORNIA
90%
On May 1, 2020, we, through our subsidiary Bayon, entered into an agreement with University of California ("UC") granting to us the exclusive rights to its pipeline of photoswitch molecules.
SENJU
SENJU
85%
In May 2025, the Company entered into an exclusive option agreement (the "Option Agreement") with Senju. Under the Option Agreement, Senju paid the Company a non-refundable upfront Option Fee of $1.2…
Kiora Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
CERTAIN-INSTITUTIONAL-INVESTORS
CERTAIN-INSTITUTIONAL-INVESTORS
92%
the Purchasers agreed to purchase from the Company
Reciprocal relationship from TOI graph: Reciprocal relationship from KPRX graph: On January 25, 2024, we entered into an agreement with TOI to co-develop and commercialize KIO-301 globally (except fo…
On January 25, 2024, we entered into an agreement with TOI to co-develop and commercialize KIO-301 globally (except for certain countries in Asia) in the field of ophthalmology.
TH-A-OPEN-INNOVATION
TH-A-OPEN-INNOVATION
90%
Under the agreement, the Company granted TOI exclusive worldwide development and commercialization rights, excluding certain countries in Asia, to KIO-301
SENJU-PHARMACEUTICAL-CO-LTD
SENJU-PHARMACEUTICAL-CO-LTD
85%
Under the agreement, the Company granted Senju an exclusive option to obtain a license to the development and commercialization rights of KIO-301
KIORA-PHARMACEUTICALS-GMBH
KIORA-PHARMACEUTICALS-GMBH
62%
recognized as revenue within the twelve months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the …
KIORA-PHARMACEUTICALS-PTY-LTD
KIORA-PHARMACEUTICALS-PTY-LTD
62%
recognized as revenue within the twelve months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the …
Kiora Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
KPRX-DEBT-10563
Warrants outstanding: 5486066
90%
xbrl warrant detail from xbrl 2025-12-31.
KPRX-DEBT-10564
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
KPRX-DEBT
Debt stack $373,586
90%
Market cache reports total debt of $373,586.
Kiora Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Kiora Pharmaceuticals, Inc..
Kiora Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
KPRX-OWNER-ADAR1-CAPITAL-MANAGEMENT-LLC
ADAR1 Capital Management, LLC
90%
13F overlay lists ADAR1 Capital Management, LLC as top holder; 17 tracked holders.
Kiora Pharmaceuticals, Inc. Extended Supply Chain Network
